N G Zaorsky1, T M Churilla1, B L Egleston2, S G Fisher3, J A Ridge4, E M Horwitz1, J E Meyer1. 1. Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA. 2. Biostatistics, Fox Chase Cancer Center, Philadelphia, USA. 3. Department of Clinical Sciences, Temple University School of Medicine, Philadelphia, USA. 4. Surgical Oncology, Fox Chase Cancer Center, Philadelphia, USA.
Abstract
Background: The purpose of our study was to characterize the causes of death among cancer patients as a function of objectives: (i) calendar year, (ii) patient age, and (iii) time after diagnosis. Patients and methods: US death certificate data in Surveillance, Epidemiology, and End Results Stat 8.2.1 were used to categorize cancer patient death as being due to index-cancer, nonindex-cancer, and noncancer cause from 1973 to 2012. In addition, data were characterized with standardized mortality ratios (SMRs), which provide the relative risk of death compared with all persons. Results: The greatest relative decrease in index-cancer death (generally from > 60% to < 30%) was among those with cancers of the testis, kidney, bladder, endometrium, breast, cervix, prostate, ovary, anus, colorectum, melanoma, and lymphoma. Index-cancer deaths were stable (typically >40%) among patients with cancers of the liver, pancreas, esophagus, and lung, and brain. Noncancer causes of death were highest in patients with cancers of the colorectum, bladder, kidney, endometrium, breast, prostate, testis; >40% of deaths from heart disease. The highest SMRs were from nonbacterial infections, particularly among <50-year olds (e.g. SMR >1,000 for lymphomas, P < 0.001). The highest SMRs were typically within the first year after cancer diagnosis (SMRs 10-10,000, P < 0.001). Prostate cancer patients had increasing SMRs from Alzheimer's disease, as did testicular patients from suicide. Conclusion: The risk of death from index- and nonindex-cancers varies widely among primary sites. Risk of noncancer deaths now surpasses that of cancer deaths, particularly for young patients in the year after diagnosis.
Background: The purpose of our study was to characterize the causes of death among cancerpatients as a function of objectives: (i) calendar year, (ii) patient age, and (iii) time after diagnosis. Patients and methods: US death certificate data in Surveillance, Epidemiology, and End Results Stat 8.2.1 were used to categorize cancerpatientdeath as being due to index-cancer, nonindex-cancer, and noncancer cause from 1973 to 2012. In addition, data were characterized with standardized mortality ratios (SMRs), which provide the relative risk of death compared with all persons. Results: The greatest relative decrease in index-cancer death (generally from > 60% to < 30%) was among those with cancers of the testis, kidney, bladder, endometrium, breast, cervix, prostate, ovary, anus, colorectum, melanoma, and lymphoma. Index-cancer deaths were stable (typically >40%) among patients with cancers of the liver, pancreas, esophagus, and lung, and brain. Noncancer causes of death were highest in patients with cancers of the colorectum, bladder, kidney, endometrium, breast, prostate, testis; >40% of deaths from heart disease. The highest SMRs were from nonbacterial infections, particularly among <50-year olds (e.g. SMR >1,000 for lymphomas, P < 0.001). The highest SMRs were typically within the first year after cancer diagnosis (SMRs 10-10,000, P < 0.001). Prostate cancerpatients had increasing SMRs from Alzheimer's disease, as did testicular patients from suicide. Conclusion: The risk of death from index- and nonindex-cancers varies widely among primary sites. Risk of noncancer deaths now surpasses that of cancer deaths, particularly for young patients in the year after diagnosis.
Authors: Gerhardt Attard; Chris Parker; Ros A Eeles; Fritz Schröder; Scott A Tomlins; Ian Tannock; Charles G Drake; Johann S de Bono Journal: Lancet Date: 2015-06-11 Impact factor: 79.321
Authors: Scott R Steele; George J Chang; Samantha Hendren; Marty Weiser; Jennifer Irani; W Donald Buie; Janice F Rafferty Journal: Dis Colon Rectum Date: 2015-08 Impact factor: 4.585
Authors: Brenda K Edwards; Anne-Michelle Noone; Angela B Mariotto; Edgar P Simard; Francis P Boscoe; S Jane Henley; Ahmedin Jemal; Hyunsoon Cho; Robert N Anderson; Betsy A Kohler; Christie R Eheman; Elizabeth M Ward Journal: Cancer Date: 2013-12-16 Impact factor: 6.860
Authors: Evan R Myers; Patricia Moorman; Jennifer M Gierisch; Laura J Havrilesky; Lars J Grimm; Sujata Ghate; Brittany Davidson; Ranee Chatterjee Mongtomery; Matthew J Crowley; Douglas C McCrory; Amy Kendrick; Gillian D Sanders Journal: JAMA Date: 2015-10-20 Impact factor: 56.272
Authors: Nicholas G Zaorsky; Brian J Davis; Paul L Nguyen; Timothy N Showalter; Peter J Hoskin; Yasuo Yoshioka; Gerard C Morton; Eric M Horwitz Journal: Nat Rev Urol Date: 2017-06-30 Impact factor: 14.432
Authors: Lixin Song; Ting Guan; Peiran Guo; Thomas C Keyserling; Courtney Van Houtven; Xianming Tan Journal: J Cancer Surviv Date: 2019-08-22 Impact factor: 4.442
Authors: Chelsea Anderson; Jennifer L Lund; Mark A Weaver; William A Wood; Andrew F Olshan; Hazel B Nichols Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-06-17 Impact factor: 4.254
Authors: Yanqun Dong; Nicholas G Zaorsky; Tianyu Li; Thomas M Churilla; Rosalia Viterbo; Mark L Sobczak; Marc C Smaldone; David Yt Chen; Robert G Uzzo; Mark A Hallman; Eric M Horwitz Journal: J Med Imaging Radiat Oncol Date: 2017-10-13 Impact factor: 1.735
Authors: Jesse F Wang; Margaret A Knoedler; Kimberly A Maciolek; Natasza M Posielski; Vania Lopez; Wade A Bushman; Sara L Best; Dan R Gralnek; Kyle A Richards Journal: Am J Clin Exp Urol Date: 2021-02-15
Authors: Jill M Hamilton-Reeves; Chelsea N Johnson; Lauren K Hand; Misty D Bechtel; Hilary L Robertson; Carrie Michel; Meredith Metcalf; Prabhakar Chalise; Nicholas J Mahan; Moben Mirza; Eugene K Lee; Debra K Sullivan; Jennifer R Klemp; Christie A Befort; William P Parker; Heather D Gibbs; Wendy Demark-Wahnefried; J Brantley Thrasher Journal: Nutr Cancer Date: 2020-12-09 Impact factor: 2.900